|Awarded On||February 15, 2023|
|Title||Studying and therapeutically targeting ferroptosis liability in BRCA1 deficient cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Boyi Gan|
|Cancer Sites||All Sites|
*Pending contract negotiation
Mutations in the tumor suppressor BRCA1 predispose to pancreatic, prostate, colorectal, and most notably, breast and ovarian cancers. Currently, inhibitors of poly (ADP-ribose) polymerase (PARPi) are used to treat cancer patients with BRCA1 deficiency; however, 40%-60% of these patients do not have a response to PARPi. Thus, novel combination treatments for patients with BRCA1-deficient cancers that are resistant to PARPi are urgently needed. Ferroptosis is an iron-dependent form of nonapoptotic cell death that is induced by a type of lipid damage on cellular membranes called lipid peroxidation. Certain drugs known as ferroptosis inducers can have potent cell killing effects by inducing fer...